CNS Response to Establish "Center of Excellence" for rEEG(SM) Application,
Research and Development
COSTA MESA, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today has it signed a letter of intent to acquire the Neuro-Therapy Clinic, P.C., a neuropsychiatric clinic in Denver, Colorado. Established in 1993, Neuro-Therapy Clinic, P.C. is a center for highly-advanced testing and treatment of neuropsychiatric problems, including learning, attentional and behavior challenges, mild head injuries, as well as depression, anxiety, bipolar and all other common psychiatric disorders. Acquisition terms were not disclosed. CNS anticipates the completion of the deal to occur within 90 days.
"The Neuro-Therapy Clinic is clearly amongst the leaders in utilizing the most advanced neuropsychiatry tools in patient assessment and treatment. Use of Referenced-EEG in guiding pharmaco-therapy has been a core competency of this clinic for over three years. In fact, the clinic has been a key contributor to the large outcomes database which comprises the backbone of our rEEG(SM) platform," noted Len Brandt, chairman and CEO of CNS Response. "Through this acquisition, CNS Response will be able to advance neurophysiology data collection, beta-test planned technological advances in rEEG(SM), advance physician training in rEEG(SM) and investigate practice- development strategies associated with rEEG(SM). Our long-standing relationship with the Neuro-Therapy Clinic and its key personnel gives us confidence that we will accomplish this vision."
Neuro-Therapy Clinic, P.C. is owned and operated by Daniel Hoffman, M.D. Upon Board approval, Dr. Hoffman will be appointed Chief Medical Officer of CNS Response.
About CNS Response
CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(SM) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG(SM) to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Janine McCargo / Jason Rando
(646) 536-7033 / 7025
|SOURCE CNS Response, Inc.|
Copyright©2007 PR Newswire.
All rights reserved